PharmGen Science announced on Friday that it has signed a strategic memorandum of understanding (MOU) with Polaris AI Pharma to collaborate on the research and development of new and improved drugs.
Under the agreement, the two companies plan to cooperate on several fronts. These include optimizing R&D processes throughout the entire drug development cycle, leveraging each other’s process technologies and research facilities, and developing product strategies for AI-driven innovation and global market expansion.
PharmGen Science boasts a pipeline of promising drug candidates. These include treatments for inflammatory bowel disease (RD1301), a liver-specific magnetic resonance imaging (MRI) contrast agent (RD1303), medications for gastroesophageal reflux disease (RD1304/1305), and an obesity treatment (RD5306).
A spokesperson for PharmGen Science stated that the company aims to achieve competitive results in new and improved drug development by combining its process technologies with AI-based research capabilities.
